Literature DB >> 24887287

Comparison of long-term outcomes associated with endovascular treatment vs surgical treatment among Medicare beneficiaries with unruptured intracranial aneurysms.

Adnan I Qureshi1, Saqib A Chaudhry, Wondwossen G Tekle, M Fareed K Suri.   

Abstract

BACKGROUND: Long-term outcomes associated with endovascular and surgical treatments for unruptured intracranial aneurysms are not well studied to date.
OBJECTIVE: To determine the 5-year risk of new intracranial hemorrhage, second procedure, and all-cause mortality in elderly patients with unruptured intracranial aneurysms who underwent either surgical or endovascular treatment.
METHODS: The study cohort included a representative sample of fee-for-service Medicare beneficiaries aged ≥65 years who underwent endovascular or surgical treatment for unruptured intracranial aneurysms with postprocedure follow-up of 4.7 (±3.0) years. Cox proportional hazards analysis was used to assess the relative risk (RR) of all-cause mortality, new intracranial hemorrhage, or second procedure for patients who underwent endovascular treatment compared with those who underwent surgical treatment after adjusting for potential confounders. The 5-year survival was estimated for both treatment groups by using Kaplan-Meier survival methods.
RESULTS: A total of 688 patients with unruptured intracranial aneurysms were treated with either endovascular (n = 398) or surgical treatment (n = 290). The rate of immediate postprocedural neurological complications (10.3% vs 3.5%, P = .001) was higher among patients treated with surgery than among those who underwent endovascular treatment. The estimated 5-year survival was 92.8% and 94.8% in patients who underwent surgical and endovascular treatments, respectively. After adjusting for age, sex, and race/ethnicity, the RRs of all-cause mortality (RR, 0.6; 95% confidence interval, 0.3-1.1) and new intracranial hemorrhage (RR, 0.4; 95% confidence interval, 0.2-0.8) were lower with endovascular treatment.
CONCLUSION: In elderly patients with unruptured intracranial aneurysms, endovascular treatment was associated with lower rates of acute adverse events and long-term all-cause mortality and new intracranial hemorrhages.

Entities:  

Mesh:

Year:  2014        PMID: 24887287     DOI: 10.1227/NEU.0000000000000450

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Comparison of clipping and coiling in elderly patients with unruptured cerebral aneurysms.

Authors:  Kimon Bekelis; Daniel J Gottlieb; Yin Su; A James O'Malley; Nicos Labropoulos; Philip Goodney; Michael T Lawton; Todd A MacKenzie
Journal:  J Neurosurg       Date:  2016-05-20       Impact factor: 5.115

2.  A cost-effectiveness analysis of screening for intracranial aneurysms in persons with one first-degree relative with subarachnoid haemorrhage.

Authors:  Esther M Hopmans; Ynte M Ruigrok; Anne Se Bor; Gabriel Je Rinkel; Hendrik Koffijberg
Journal:  Eur Stroke J       Date:  2016-10-19

3.  New York State: Comparison of Treatment Outcomes for Unruptured Cerebral Aneurysms Using an Instrumental Variable Analysis.

Authors:  Kimon Bekelis; Symeon Missios; Shannon Coy; Robert J Singer; Todd A MacKenzie
Journal:  J Am Heart Assoc       Date:  2015-07-13       Impact factor: 5.501

Review 4.  Unruptured Cerebral Aneurysms in Elderly Patients.

Authors:  Tomohito Hishikawa; Isao Date
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-04-19       Impact factor: 1.742

Review 5.  Unruptured cerebral aneurysms in elderly patients: key challenges and management.

Authors:  Nicholas Caffes; Nicole Wenger; Gregory Cannarsa; Jeffrey Oliver; Chimdiya Onwukwe; Dheeraj Gandhi; J Marc Simard
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

6.  Influence of Age-Related Complications on Clinical Outcome in Patients With Small Ruptured Cerebral Aneurysms.

Authors:  Jianfeng Zheng; Xiaochuan Sun; Xiaodong Zhang
Journal:  Front Neurol       Date:  2020-03-05       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.